Orexo AB
STO:ORX
Orexo AB
STO:ORX
Price:
22.15
SEK
-1.34%
Market Closed
Market Cap:
kr768.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Orexo AB
STO:ORX
|
SE |
|
B
|
Brand Concepts Ltd
NSE:BCONCEPTS
|
IN |
|
A
|
Anupam Finserv Ltd
BSE:530109
|
IN |
|
Orizon Valorizacao de Residuos SA
BOVESPA:ORVR3
|
BR |
|
MAG Silver Corp
TSX:MAG
|
CA |
|
J
|
Juniper Hotels Ltd
NSE:JUNIPER
|
IN |
|
B
|
Benara Bearings and Pistons Ltd
BSE:541178
|
IN |
|
CG Power and Industrial Solutions Ltd
NSE:CGPOWER
|
IN |
|
Spice Private Equity AG
SIX:SPCE
|
CH |
|
China Resources Mixc Lifestyle Services Ltd
HKEX:1209
|
CN |
|
Biotest AG
XETRA:BIO
|
DE |
|
G
|
Gaming Technologies Inc
OTC:GMGT
|
US |
|
G
|
Gunkul Engineering PCL
SET:GUNKUL
|
TH |
|
Bourse Direct SA
F:BD6
|
FR |
Multiples-Based Value
The Multiples-Based Value of one
ORX
stock under the Base Case scenario is
hidden
SEK.
Compared to the current market price of 22.15 SEK,
Orexo AB
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ORX Multiples-Based Value
LOCKED
Multiples Across Competitors
ORX Competitors Multiples
Orexo AB Competitors
Orexo AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
Orexo AB
STO:ORX
|
764.3m SEK | 29.4 | 1.2 | -1.2 | -1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
